| Sustained effect of the aromatase inhibitors anastrozole and letrozole on endometrial thickness in patients with endometrial hyperplasia and endometrial carcinoma. | |
| | |
MedLine Citation:
|
PMID: 19301987 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate whether there may be a role for aromatase inhibitors (AIs) in the treatment of endometrial hyperplasia (EH) and endometrial adenocarcinoma (EA) in postmenopausal women, a retrospective study on the effect of aromatase inhibitors (anastrozole or letrozole) was conducted for 16 patients who were not amenable to surgical treatment. MAIN OUTCOME MEASURE: Resolution of endometrial thickening measured by transvaginal ultrasound at 3-month intervals; the response of metastases was assessed by standard oncological criteria. RESULTS: In all, 16 patients were studied. The BMI of 13 of the 16 patients was known and ranged from 20.7 to 47.7 (mean 34.5) kg/m(2). During treatment with AIs, mean endometrial thickness in the eight patients with EH decreased progressively by 81.7% from 14.7 mm at the start of treatment to 2.7 mm following 36 months of treatment. A greater original mean endometrial thickness of 17 mm was seen in the four patients with localised EA, this fell progressively by 67.1% to 5.6 mm following 36 months of treatment. No responses were seen in four patients with metastatic disease. CONCLUSION: Our results indicate that treatment of EH with anastrozole or letrozole can reduce endometrial thickness as seen ultrasonically, and that in some cases AI treatment can reduce endometrial thickness in patients with localised EA. We found no evidence to indicate that AI treatment prevents disease progression in patients with metastatic EA. Further investigations will be necessary to validate our findings from this small retrospective study and to compare AI inhibitor treatment with topical progestogen therapy. |
| | |
Authors:
|
L C Barker; I R Brand; S M Crawford |
Related Documents
:
|
2307247 - Luteal rescue in in vitro fertilization-embryo transfer. 7064027 - Female sterilization - a follow-up report. 10924627 - Hysteroscopic endometrial ablation is an effective alternative to hysterectomy in women... 2512467 - Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density. 6728087 - New acute peritoneal dialysis technique: wire-guide insertion and long-term indwelling ... 12072597 - What is an appropriate indication for endoscopic papillary balloon dilation? |
Publication Detail:
|
Type: Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Current medical research and opinion Volume: 25 ISSN: 1473-4877 ISO Abbreviation: Curr Med Res Opin Publication Date: 2009 May |
Date Detail:
|
Created Date: 2009-04-29 Completed Date: 2009-07-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0351014 Medline TA: Curr Med Res Opin Country: England |
Other Details:
|
Languages: eng Pagination: 1105-9 Citation Subset: IM |
Affiliation:
|
Oncology Department, Airedale General Hospital, Steeton, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents / pharmacology, therapeutic use Aromatase Inhibitors / pharmacology*, therapeutic use Carcinoma / drug therapy*, pathology Disease Progression Endometrial Hyperplasia / drug therapy*, pathology Endometrial Neoplasms / drug therapy*, pathology Endometrium / drug effects*, pathology Female Humans Middle Aged Neoplasm Metastasis Nitriles / pharmacology*, therapeutic use Organ Size / drug effects Retrospective Studies Time Factors Triazoles / pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Aromatase Inhibitors; 0/Nitriles; 0/Triazoles; 112809-51-5/letrozole; 120511-73-1/anastrozole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Breastmilk from allergic mothers can protect offspring from allergic airway inflammation.
Next Document: Change in formulation and its potential clinical and pharmacoeconomic value: example of extended rel...